Hudson Bay Capital Management LP Grows Position in Vir Biotechnology, Inc. $VIR

Hudson Bay Capital Management LP increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 31.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 911,882 shares of the company’s stock after purchasing an additional 215,882 shares during the quarter. Hudson Bay Capital Management LP owned 0.66% of Vir Biotechnology worth $5,207,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in Vir Biotechnology during the second quarter worth about $35,000. Federated Hermes Inc. raised its stake in shares of Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after acquiring an additional 4,899 shares during the period. Daiwa Securities Group Inc. raised its stake in shares of Vir Biotechnology by 2,200.6% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after acquiring an additional 11,773 shares during the period. Truist Financial Corp acquired a new position in shares of Vir Biotechnology in the 3rd quarter worth approximately $63,000. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Vir Biotechnology by 25.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 13,159 shares of the company’s stock worth $66,000 after acquiring an additional 2,700 shares during the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Needham & Company LLC upped their price target on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays lifted their price objective on Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday, February 24th. Finally, Raymond James Financial upgraded Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.44.

Vir Biotechnology Stock Down 3.0%

Shares of VIR opened at $9.10 on Friday. The company has a market cap of $1.27 billion, a P/E ratio of -2.88 and a beta of 1.65. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.94. The firm’s 50 day moving average price is $8.06 and its 200 day moving average price is $6.58.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The company had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. During the same quarter last year, the company posted ($0.76) EPS. The firm’s revenue was up 417.8% compared to the same quarter last year. Research analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $9.51, for a total transaction of $209,220.00. Following the completion of the sale, the director directly owned 1,122,391 shares of the company’s stock, valued at approximately $10,673,938.41. The trade was a 1.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Backer Marianne De sold 14,762 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $9.53, for a total value of $140,681.86. Following the sale, the chief executive officer owned 1,020,704 shares of the company’s stock, valued at approximately $9,727,309.12. The trade was a 1.43% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 177,546 shares of company stock valued at $1,522,174. Insiders own 16.00% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.